AR085431A1 - Complejo de resinato de doxilamina - Google Patents

Complejo de resinato de doxilamina

Info

Publication number
AR085431A1
AR085431A1 ARP120100881A ARP120100881A AR085431A1 AR 085431 A1 AR085431 A1 AR 085431A1 AR P120100881 A ARP120100881 A AR P120100881A AR P120100881 A ARP120100881 A AR P120100881A AR 085431 A1 AR085431 A1 AR 085431A1
Authority
AR
Argentina
Prior art keywords
doxylamine
medicine
preparation
cation exchange
weakly acidic
Prior art date
Application number
ARP120100881A
Other languages
English (en)
Inventor
Cot Jordi Font
Aldea Albert Falivene
Ranzani Luis Soler
Pujals Gemma Casadevall
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of AR085431A1 publication Critical patent/AR085431A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Complejo de resinato de doxilamina que comprende doxilamina unida a una resina de intercambio catiónico sintética débilmente ácida, tal como un copolímero de ácido metacrílico y divinilbenceno. Un procedimiento para su preparación que comprende poner en contacto una resina de intercambio catiónico sintética débilmente ácida con doxilamina o una sal farmacéuticamente aceptable de la misma y su uso para la preparación de composiciones farmacéuticas, tales como comprimidos masticables o comprimidos disgregables orales de liberación inmediata. Complejo de resinato de doxilamina para su uso como medicamento, preferiblemente como medicamento para su uso en el tratamiento del insomnio ocasional.
ARP120100881A 2011-03-18 2012-03-16 Complejo de resinato de doxilamina AR085431A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11382072A EP2500016A1 (en) 2011-03-18 2011-03-18 Doxylamine resinate complex

Publications (1)

Publication Number Publication Date
AR085431A1 true AR085431A1 (es) 2013-10-02

Family

ID=44279867

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100881A AR085431A1 (es) 2011-03-18 2012-03-16 Complejo de resinato de doxilamina

Country Status (3)

Country Link
EP (2) EP2500016A1 (es)
AR (1) AR085431A1 (es)
WO (1) WO2012126770A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103417541A (zh) * 2013-08-22 2013-12-04 万特制药(海南)有限公司 一种包含齐拉西酮及其盐的药物树脂盐及其制备方法
PT3185856T (pt) * 2014-08-29 2018-10-09 Duchesnay Inc Formulação de libertação plurimodal de doxilamina e pirodoxina e/ou seus metabolitos ou sais
US11154495B2 (en) * 2015-04-07 2021-10-26 Church & Dwight Co., Inc. Multicomponent gummy compositions with soft core
EP3398590A1 (de) * 2017-05-02 2018-11-07 Stada Arzneimittel Ag Schmelztablette, enthaltend ein h1-antihistaminika

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563294A1 (en) 1990-12-21 1993-10-06 Richardson-Vicks, Inc. Polyamine drug-resin complexes
JP2005325070A (ja) * 2004-05-14 2005-11-24 Ss Pharmaceut Co Ltd 睡眠改善剤

Also Published As

Publication number Publication date
EP2500016A1 (en) 2012-09-19
EP2536401A1 (en) 2012-12-26
WO2012126770A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CR20150114A (es) Composición farmacéutica recubierta que contiene regorafenib
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
ECSP088490A (es) Forma farmacéutica oral que contiene como principios activos un inhibidor de la bomba de protones junto con ácido acetilsalicílico
CL2009000598A1 (es) Composicion farmaceutica oral que comprende particulas de liberacion pulsatil controlada en el tiempo (tpr), que contienen un farmaco poco soluble debilmente basico y un acido organico separados por una capa de liberacion sostenida, y particulas de liberacion rapida (rr); capsula que la comprende; y su uso para tratar emesis.
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
GT201400069A (es) Composiciones farmaceuticas
AR075369A1 (es) Comprimidos para terapia de combinacion para el tratamiento de infecciones virales.
ECSP13012847A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación.
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
DOP2014000269A (es) Nueva dosificación y formulación
AR085431A1 (es) Complejo de resinato de doxilamina
AR094851A1 (es) COMPUESTOS BICíCLICOS COMO AGONISTAS DE S1P₁
PE20151543A1 (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
CL2013003176A1 (es) Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol.
AR093252A1 (es) Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación
CR20110674A (es) Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del ST
HN2010001775A (es) Composicion farmaceutica oral que comprende la combinacion de una sal de keterolaco y vitaminas del complejo b

Legal Events

Date Code Title Description
FA Abandonment or withdrawal